These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 36853300)
1. Trimodality Therapy in which Concurrent Chemoradiation with Concomitant Boost in Muscle Invasive TCC Urinary Bladder Cancer. Youssief Mohammed AA; Gamal DA; Abd Elzaher AR; Hasaballah A Asian Pac J Cancer Prev; 2023 Feb; 24(2):517-524. PubMed ID: 36853300 [TBL] [Abstract][Full Text] [Related]
2. Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival. Lee CY; Yang KL; Ko HL; Huang RY; Tsai PP; Chen MT; Lin YC; Hwang TI; Juang GD; Chi KH Radiat Oncol; 2014 Sep; 9():213. PubMed ID: 25248470 [TBL] [Abstract][Full Text] [Related]
3. Muscle-invasive bladder cancer treated with TURB followed by concomitant boost with small reduction of radiotherapy field with or without of chemotherapy. Nowak-Sadzikowska J; Skóra T; Szyszka-Charewicz B; Jakubowicz J Rep Pract Oncol Radiother; 2016; 21(1):31-6. PubMed ID: 26900355 [TBL] [Abstract][Full Text] [Related]
4. Gemcitabine based trimodality treatment in patients with muscle invasive bladder cancer: May neutrophil lymphocyte and platelet lymphocyte ratios predict outcomes? Hurmuz P; Ozyigit G; Kilickap S; Esen CSB; Akdogan B; Ozen H; Akyol F Urol Oncol; 2021 Jun; 39(6):368.e19-368.e29. PubMed ID: 33189528 [TBL] [Abstract][Full Text] [Related]
5. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control. Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605 [TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer. Jiang DM; Jiang H; Chung PWM; Zlotta AR; Fleshner NE; Bristow RG; Berlin A; Kulkarni GS; Alimohamed NS; Lo G; Sridhar SS Clin Genitourin Cancer; 2019 Feb; 17(1):38-45. PubMed ID: 30686350 [TBL] [Abstract][Full Text] [Related]
11. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study. Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M; Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206 [TBL] [Abstract][Full Text] [Related]
12. Transurethral Resection of Bladder Tumor (TUR-BT) then Concomitant Radiation and Cisplatin Followed by Adjuvant Gemcitabine and Cisplatin in Muscle Invasive Transitional Cell Carcinoma (TCC) of the Urinary Bladder. Ibrahim SM; Abd El-Hafeez ZM; Mohamed EM; Elsharawy IA; Kamal KM J Egypt Natl Canc Inst; 2007 Mar; 19(1):77-86. PubMed ID: 18839038 [TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes in treatment of invasive bladder cancer with concomitant boost and accelerated hyperfractionated radiation therapy. Canyilmaz E; Yavuz MN; Serdar L; Uslu GH; Zengin AY; Aynaci O; Haciislamoglu E; Bahat Z; Yoney A Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):562-9. PubMed ID: 25160608 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of efficacy and toxicity in two different hypofractionated 3D-conformal external beam radiotherapy schedules in localised muscle invasive bladder cancer. Kouloulias V; Mosa E; Tolia M; Kantzou I; Koliarakis N; Platoni K; Georgakopoulos I; Siatelis A; Sarris G; Beli I; Chrisofos M; Kelekis N J BUON; 2013; 18(4):942-8. PubMed ID: 24344021 [TBL] [Abstract][Full Text] [Related]
15. Clinical and dosimetric outcomes of image-guided, dose-painted radiotherapy in muscle invasive bladder cancer. Navarro-Domenech I; Arulanantham S; Liu ZA; Tjong M; Kong V; Malkov V; Tadic T; Fleshner N; Kulkarni G; Zlotta AR; Catton C; Berlin A; Sridhar S; Jiang DM; Chung P; Raman S Radiat Oncol; 2023 Sep; 18(1):154. PubMed ID: 37730609 [TBL] [Abstract][Full Text] [Related]
16. Accelerated superfractionated radiotherapy with concomitant boost for invasive bladder cancer. Yavuz AA; Yavuz MN; Ozgur GK; Colak F; Ozyavuz R; Cimsitoglu E; Ilis E Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):734-45. PubMed ID: 12788179 [TBL] [Abstract][Full Text] [Related]
17. Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer. Chen WC; Liaw CC; Chuang CK; Chen MF; Chen CS; Lin PY; Chang PL; Chu SH; Wu CT; Hong JH Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):726-33. PubMed ID: 12788178 [TBL] [Abstract][Full Text] [Related]